Christophe Bourdon, Orphazyme
Orphazyme plans to lay off most of its staff following a string of failures for lead 'pipeline-in-a-product'
Danish biopharma Orphazyme has been on a roller coaster of a ride lately, and the company plummeted down a bit further on Monday with the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
